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Pulmonary complications are an important cause for treatment-related morbidity and mortality in
hematopoietic cell transplantation (HCT) in children. The aim of this study was to investigate the yield of our
pre-HCT pulmonary screening program. We also describe our management guidelines based on these ﬁnd-
ings and correlate them with symptomatic lung injury after HCT. Since 2008, all patients undergo a dedicated
pulmonary screening consisting of pulmonary function test (PFT), chest high-resolution computed tomog-
raphy (HRCT), and bronchial alveolar lavage (BAL) before HCT. We systematically evaluated the yield during
the ﬁrst 5 years of our screening program. We included 142 consecutive children. In 74% of patients,
abnormalities were found. In 66% of patients, 1 or more PFT results were <80% of normal. Chest HRCT showed
abnormalities in 55%; 19% of these abnormalities were considered “clinically signiﬁcant.” BAL was abnormal
in 43% of patients; respiratory viruses (PCR) were found in 35 patients, fungi (antigen or culture) in 21, and
bacteria (culture) in 22. All 3 screening tests contributed separately to clinically relevant information
regarding pulmonary status in these pre-HCT children. In 46 patients (33%), screening results had diagnostic
and/or therapeutic implications. We found an association between pre-SCT HRCT ﬁndings and lung injury
after transplantation. Pre-HCT screening with the combination of 3 modalities, reﬂecting different domains of
respiratory status (function, structure, and microbial colonization), reveals important abnormalities in a
substantial number of patients. Whether this improves patient outcome requires further investigation.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Hematopoietic cell transplantation (HCT) is a curative
treatment for various diseases. Pulmonary complications,
both infectious and noninfectious, are frequently seen in
patients undergoing HCT. In children, the incidence of
pulmonary complications varies from 25% to 74% and is
associated with a signiﬁcantly increased risk for mortality
[1-3]. Because of the risk of life-threatening complications
of the procedure, patients are routinely screened for HCT
eligibility. Lung screening can potentially impact selectionedgments on page 1626.
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ty for Blood and Marrow Transplantation.of HCT patients as well as affect preemptive treatment and
prognosis.
Invasive fungal infections (IFI) are an important cause of
morbidity and mortality during HCT. Diagnostic imaging,
culturing pathogens, and antigen detection can be helpful to
identify patients at high risk for IFI, whichmay guide therapy
[4].
Also, respiratory viruses (RV) may have impact on the
overall survival of HCT, either directly as a cause of pneu-
monitis in the severe immune-compromised patient or
indirectly by triggering allo-immunity in the setting of allo-
geneic transplantation [5].
In 2008, we implemented extensive pre-HCT lung
screening, which includes pulmonary function test (PFT),
chest high-resolution computed tomography (HRCT), and
bronchial alveolar lavage (BAL) in all patients. Here, we
evaluate the yield of such an extensive pulmonary screening
Table 1
Patient Characteristics
Characteristic Value
Age, yr
Median (range) 7.0 (.2-19.4)
Gender
Female 54
Male 88
Underlying disease
Immunedeﬁciency* 27
Leukemia/lymphoma 60
Bone marrow failurey, bone marrow
disease without chemotherapyz
30
Inborn error of metabolismx 25
* Immune deﬁciencies include combined immune deﬁciency, severe
combined immune deﬁciency, hemophagocytic lympho histiocytosis,
autoimmune lymphoproliferative syndrome, and chronic granulomatous
disease. Leukemia includes acute lymphoblastic leukemia and acute
myeloid leukemia.
y Bone marrow failure includes Fanconi anemia, congenital agranulocy-
tosis, and thallasemia.
z Bone marrow diseases not pretreated with chemotherapy include
myelodysplastic syndrome and juvenile myelomonocytotic leukemia.
x Inborn errors of metabolism includes predominantly Hurler syndrome.
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these ﬁndings as well as the outcome of patients.
MATERIALS AND METHODS
All consecutive pediatric patients undergoing a ﬁrst allogeneic HCT in
our center between January 2008 and August 2013 were included. Patients
were enrolled in the HCT research protocol after providing written informed
consent for data collection and analysis, according to national ethical reg-
ulations (Ethical Commission Number 05/143 and 11/063K). Patient char-
acteristics (age, gender, underlying disease), clinical symptoms, results of
pulmonary screening tests, and occurrence of symptomatic lung disease
after HCT was registered.
Pulmonary Screening
Standard pre-HCT pulmonary screening is performed in theweek before
transplantation and consists of a PFT, HRCT scan, and BAL.
PFT includes spirometry, whole body plethysmography, and measure-
ment of carbon monoxide diffusion capacity. Measurements are performed
in children aged 5 years and older, according to American Thoracic Society/
European Respiratory Society criteria, using calibrated pneumotachometer
systems (Jaeger, Hochberg, Germany). Values are expressed as percentage of
predicted values for age, race, sex, and height-matched controls (The
Utrecht data set, Koopman [6]).
Forced expiratory volume in 1 second, forced vital capacity, total lung
capacity, and lung diffusion capacity for CO, corrected for hemoglobin and
alveolar volume < 80% of predicted values are considered to be abnormal.
Residual volume of >25% of total lung capacity is considered to be abnormal
and suggestive for trapped air. HRCT scans are acquired using a 16-detector
row scanner (Philips Medical Systems, Best, Netherlands). For infants and
young children, scans are obtained at 25-cm H2O pressure (inspiration) and
0-cm H2O pressure (expiration). For older children, who were able to
cooperate with breath hold instruction, scans were obtained at full inspi-
ration and at end of exhalation. Inspiration images are obtained using ﬁxed
90 kVp and 18 to 60mAs (depending on bodyweight). For expiration images,
we used 90 kVp and 11 mAs. Acquisition was volumetric thin-slice for both
inspiratory and expiratory computed tomography.
All HRCT scans were assessed by a pediatric radiologist. Fleischner
Society terms for thoracic imaging were used [7]. All abnormalities, as stated
in the radiology report, were registered. Those abnormalities with clinical
implications, such as antimicrobial treatment, guided lung biopsy or
diuretics, were deﬁned as clinically signiﬁcant.
BAL was performed under general anesthesia.
BAL ﬂuid was cultured and processed in accordance with standard
microbiological procedures. Galactomannan (GM) tests are performed using
BioRad Platelia Aspergillus EIA. Any positive culture or GM levels > .5 was
considered to be abnormal.
Nucleic acids are extracted using the total nucleic acid protocol with the
MagNA pure LC nucleic acid isolation system (Roche Diagnostics, Basel,
Switzerland). For detection of RNA-viruses cDNA is synthesized by using
MultiScribe reverse transcriptase and random hexamers (Applied Bio-
systems, Foster City, CA). Detection of viral and atypical pathogens was
performed in parallel, using real-time PCR assays speciﬁc for the following
viruses: bocavirus, Human herpesviruse6, respiratory syncytial virus,
inﬂuenzavirus A and B, parainﬂuenzavirus 1 to 4, rhinoviruses, adenovi-
ruses, human coronavirus OC43, NL63 and 229E, human metapneumovirus,
and Mycoplasma pneumoniae. Real-time PCR procedures were performed
as described previously [8]. Any positive PCR is considered to be abnormal.
The total costs for the pulmonary screening were approximately 900
euro. Chest HRCT costs 300 euro, RV panel PCR 495, bacterial cultures 11
euro, GM 12 euro, PFT (complete) cost 48 euro.
For further analysis, patients were classiﬁed according to their risk for
pre-HCT pulmonary problems, based on underlying disease, immune
competence, infection risk, and pretreatment with potentially lung-toxic
therapy. We distinguished 3 groups of patients: those with an inherited
immune deﬁciency, those with a malignant disease and chemotherapy
before transplantation, and those with inborn errors of metabolism, mild
bone marrow failure, and malignancies without chemotherapeutic
treatment.
Standard Antimicrobial Prophylaxis
Antibiotic prophylaxis involved daily ciproﬂoxacin and ﬂuconazole,
from the start of conditioning until the resolution of neutropenia. Additional
prophylaxis against Streptococcus viridans was given with cefazoline in the
mucositis phase. Empiric antibiotic treatment for febrile neutropenia
included vancomycin and ceftazidime. Pneumocystis jeroveci pneumonia
prophylaxis was started from 1 month after transplantation as cotrimox-
azole 3 times a week. In case of positive serology for herpes simplex virus in
all patients, and in case of positive serology for varicella zoster virus in cordblood transplantation recipients, prophylaxis with aciclovir was given. No
other antiviral prophylaxis was given. In patients at high risk for IFI, ac-
cording to our protocol, based on pretreatment, duration of neutropenia,
and history of fungal infection, Aspergillus prophylaxis was given with daily
voriconazole or twice weekly amphotericin B.Practical Guidelines according to Findings on Pulmonary Screening
Patients with severely impaired PFT (<50% of normal) were considered
to have an unacceptable high risk for treatment-related mortality and were
excluded for HCT.
Patients with RV from BAL were considered to have a high risk for
alloimmune-mediated lung syndromes. In elective HCT procedures, HCT
was postponed until the RV was cleared. In other casesdwhen the under-
lying disease did not allow treatment delaydtapering of immune sup-
pression after HCT was adjusted to prevent alloimmune-mediated lung
syndromes. In cases with probable fungal disease (positive cultures or GM
from BAL), antifungal treatment was considered. Patients with positive
bacterial cultures from BAL were not treated, unless pulmonary symptoms
developed. Bacterial culture results guide the choice of empirical antibiotic
treatment for neutropenic fever after HCT.
In patients with nodular lesions on HRCT, lung biopsy was considered to
identify the possible infectious cause and antimicrobial resistance pattern.
In patients with possible or proven IFI based on BAL ﬁndings, biopsy
results, or HRCT ﬁndings, antifungal treatment was started and granulocyte
transfusions or haploidentical stem cell support (combined with cord blood
grafts) were considered.Statistical Analysis
Calculation of mean values and standard deviation was done for PFTs.
Comparing the results with predicted values for age, race, sex, and height-
matched controls was done using t-test (test value 100%). Comparison of
the means between the different disease groups was done using ANOVA.
The chi-square test was used for comparison of proportions between 2 or
more groups. Differences with a P value of < .05 were considered statisti-
cally signiﬁcant. Associations between pre-HCT pulmonary screening ﬁnd-
ings and clinicallymanifested lung injury after HCTwere analyzed using Cox
proportional hazard models. Dichotomous outcomes were used as depen-
dent variables. Univariate predictors with a P value of < .05 were used for
multivariate analysis. All statistics were done using SPSS 21.RESULTS
Patient Cohort
We included 142 consecutive children receiving a ﬁrst
allogeneic HCT. Apart from mild upper respiratory tract
symptoms in some, all patients were asymptomatic for lung
disease at the time of pre-HCT screening. Patient character-
istics are shown in Table 1.
Figure 1. Prevalence of HRCT abnormalities before HCT, per disease group.
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all; 2 of them were under 4 months of age. In 122 patients
(86%), all planned screening modalities could be performed.
In 19 children, only some of the tests were done either for
logistic reasons (n ¼ 9) or because screening BAL was the
only reason for general anesthesia, which was then consid-
ered a disproportional invasive procedure (n ¼ 7). In 2 chil-
dren above the age of 5, PFT was not feasible because of
developmental delay. In 1 patient, HRCT was omitted
because of the risk of irradiation damage related to under-
lying disease (Fanconi anemia).
PFT
PFT were performed in 83 patients. This was 94% of all
patients in whom we were able to perform these tests, ac-
cording to age and developmental level. Results are shown in
Table 2. We found PFT patterns of restrictive and obstructive
lung disease as well as diffusion abnormalities with forced
expiratory volume in 1 second, mean 82.7% (SD 11.5); forced
vital capacity, mean 87.8% (SD 14.1); total lung capacity, 86%
(SD 10.2); and lung diffusion capacity for CO, corrected for
hemoglobin and alveolar volume, 81.9% (SD 18.5). Compared
with the reference population with values of 100% (SD 12),
all differences were statistically signiﬁcant; with P values
of < .0001. There was no difference in abnormalities in PFT
between the different disease categories, see Table 2.
HRCT
Chest HRCT was performed in 137 (96%) patients. In 74
patients (55%), abnormalities were seen; in 63 of 74 patients
(85%) these ﬁndings were “new” ﬁndings. In the group of
patients without pretreatment with chemotherapy or
immune deﬁciency, the incidence of HRCT abnormalities
before HCT was signiﬁcantly lower than in the other patients
(Figure 1). In 18 patients (13%), clinically signiﬁcant abnor-
malities were found. Four (3%) had lesions suspect for fun-
gus. Fourteen patients (10%) showed other abnormalities,
including bronchiectasis, pleural effusion, consolidations,
and aspeciﬁc nodules > 1 cm. These were new ﬁndings in
8 of 14 patients (57%). Most clinically signiﬁcant abnormal-
ities were found in the subgroup of patients with immune
deﬁciencies, but this did not reach statistical signiﬁcance
(Figure 1).
BAL
BAL was performed in 127 (90%) patients. Unfortunately,
for logistic reasons, it was not always possible to do all
microbial tests. Overall, in 47% of tested patients, 1 or more ofTable 2
PFT before HCT
All n ¼ 83 Mean Difference from Reference
Population (1-sided t-test)
Immun
Deﬁcie
n ¼ 13
FEV1 (% pred) 82.7 (SD 11.5) 17.3 [95% CI, 20.5-14.1; P < .0001] 83.5 (1
FVC (% pred) 87.8 (SD 14.1) 12.2 [95% CI, 16.2-8.2; P < .0001] 91.5 (1
TLC (% pred) 86.9 (SD 10.2) 14.5 [95% CI, 17.9-11.1; P < .0001] 92.2 (8
RV/TLC 25.2 (SD 5.7) 25.4 (5
TLCO (% pred) 81.9 (SD 18.5) 18 [95% CI, 25.8-10.4; P < .0001] 85.7 (2
Abnormal PFT
(<80% pred or
RV/TLC > 25)
8 patie
FEV1 indicates forced expiratory volume in 1 second; % pred, percentage of predicte
capacity; TLC, total lung capacity; RV, residual volume; TLCO, lung diffusion capac
Mean values and SD in all patients, compared with reference population, mean vathe microbial tests were positive. Positive PCR for RV was
found in 35 (31%) of tested patients. Rhinovirus was themost
frequently detected virus (Table 3). In 21 (17%) patients, we
found microbial evidence of fungal colonization either with
positive cultures or GM. In only 2 patients, a positive GM
corresponded with a positive culture for Aspergillus; in 1
patient with a positive Aspergillus culture, GM from BAL was
negative. The positive ﬁndings for the whole cohort are
shown in Table 3. In patients under 5 years of age, the in-
cidences of BAL abnormalities in general, RV positivity, and
bacteria positivity were signiﬁcant higher than in older
patients (P values of .001, .01, and .0003 respectively).Relationship between Different Tests
Figure 2 shows the yield of all screening tests. Abnor-
malities were found in tests of 74% of patients. We found
abnormalities in radiological tests among patients with
normal and abnormal PFTs, as well as positive microbial test
results in patients with normal PFTs and normal HRCT.Impact on Outcome
In 46 patients, the screening outcome had implications,
such as guided BAL/lung biopsy (n ¼ 8), change in antifungal
treatment/prophylaxis (n ¼ 12), granulocyte transfusions
(n ¼ 2), addition of haploidentical stem cells (n ¼ 3), post-
ponement of HCT (n ¼ 11), or guided tapering of immune
suppressive agents (n ¼ 35). These interventions overlapped
in some patients.e-
ncy
Malignant Disease
Pretreated with
Chemotherapy n ¼ 41
Bone Marrow Disease,
Inborn Errors of
Metabolism No
Pretreatment n ¼ 29
Difference
between
Disease Groups
(ANOVA)
2.9) 81.3 (10.1) 84.3 (12.6) NS
4.6) 86.3 (12.7) 88.1 (15.7) NS
.3) 83.8 (10.8) 84.5 (7.6) NS
.8) 23.6 (4.9) 27.5 (6.0) NS
1.6) 81.0 (19.8) 81.2 (13.2) NS
nts (62%) 28 patients (68%) 19 patients (65%)
d value; 95% CI, 95% conﬁdence interval; NS, not signiﬁcant; FVC, forced vital
ity for CO.
lues and SD per disease group, and comparison between disease groups.
Table 3
Results from Screening Tests in BAL before HCT
Test Viral PCR (n ¼ 113) Bacterial Culture (n ¼ 123) Fungal Culture (n ¼ 123) GM*
(n ¼ 119)
No. positive, (%) 35 (31%) 22 (17%) 8 (7%) 17 (14%)
21 (18%)y
Rhinovirus: 18; RSV: 3; Inﬂuenzavirus: 2;
Corona: 2; Adenovirus: 2; Bocavirus: 1;
Metapneumovirus: 1;
Parainﬂuenzavirus: 1; mixed viruses: 5
H. inﬂuenza: 7; Streptococci: 3;
Mycoplasma Pn: 1; Morganella: 1;
Pseudomonas: 1; Stenotrophomonas: 1;
Klebsiella: 1; mixed: 7
Candida species: 2; Aspergillus
species: 3; Penicillium species: 3
* Galactomannan in BAL > .5 ¼ positive.
y There was overlap between fungal culture results and galactomannan ﬁndings in BAL (2 of 3 Aspergillus-positive patients were also galactomannan positive,
1 patient with candida and 1 with penicillium also had positive GM) so 21 patients were considered positive for fungus.
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gressive signs of inﬁltrative fungal infection. Antifungal
therapy was intensiﬁed in 3 based on resistance pattern of
the cultured pathogen. In 2 patients, we postponed HCT. In 3
cord blood transplant recipients, we added haploidentical
CD34þ cells from a family donor for early myeloid support,
and in 2 patients we gave granulocyte transfusions during
the period of neutropenia. One patient had graft rejection
and showed fatal progression of Aspergillus infection in
prolonged neutropenia. The 3 others did not show progres-
sion of infection, and therapy could be stopped safely after
engraftment.
No patient with RV or bacteria isolated showed progres-
sion of pulmonary infection during HCT. None of the patients
with isolated positive ﬁndings for fungus from BAL, of whomFigure 2. Overview results of pthe majority received intensiﬁcation of fungal prophylaxis/
treatment, developed pulmonary fungal disease.
Cox regression analysis did not show a relation between
pre-HCT screening ﬁndings in BAL or PFT and symptomatic
lung injury after HCT. A clinically signiﬁcant abnormality
on chest HRCT before HCT, however, was a predictor for the
development of immune-mediated lung injury after HCT
(hazard ratio, 3.49; 95% conﬁdence interval, 1.07 to 11.35;
P ¼ .037).
DISCUSSION
Our study in 142 pediatric patients shows that pulmonary
screening before HCT with PFT, HRCT, and BAL is feasible. We
could perform all the tests in the majority of patients (86%).
Abnormalities were found in 72% of patients. In 32% ofre-HCT screening tests.
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treatment according to guidelines. Only in patients with
clinically signiﬁcant chest HRCT, abnormalities a higher
incidence of lung-injury was noted after HCT. Although not
negligible, the costs seem justiﬁed in relation to the ﬁndings.
It is well known that pulmonary function declines early
after HCT [9,10], and some studies have shown a continuous
decline without reaching a plateau during prolonged follow-
up [9]. Several studies have demonstrated that impaired
PFT before transplantation increases the risk for
post-transplantation lung complications and mortality
[1,9,11-14]. Possible explanations for these observations are
that patients can have such marginal lung reserve capacity,
endangering a period of critical illness and/or further lung
toxic events. Also, in patients with pre-existing lung injury,
this organ may be at increased risk for allo-immune phe-
nomena, such as graft-versus-host disease.
We evaluated the yield of HRCT scanning. Omitting HRCT
from our screening in this cohort would have missed 7 (5%)
children with abnormalities, including 2 of the 4 with inﬁl-
trative lesions suspect for fungus. On the other hand, HRCT
leads to radiation exposure and may require general anes-
thesia in children and, therefore, deserves critical appraisal.
The relevance of abnormal ﬁndings on HRCT are a matter of
debate. In the radiological reports in this study, abnormal-
ities were described in 55% of patients. Because the severity
of the reported abnormalities varied considerably, we chose
to take into account those HRCT ﬁndings which had
“signiﬁcant clinical meaning” at time of transplantation, such
as consolidations requiring antibiotic or antifungal therapy,
bronchiectasis as a risk factor for infections warranting
change in prophylaxis, or pleural effusions requiring
diuretics. In most patients, a plain chest x-ray was available
but showed abnormalities in only 50%, and, of note, did not
show any abnormalities in the 4 patients with signs of
invasive fungal infection on HRCT (data not shown).
The yield of BAL procedures was high in our study.
Omitting BAL would have missed 19 (14%) patients with
fungal colonization and 35 (25%) with RV. All these patients
had normal HRCT scans and no signiﬁcant pulmonary
symptoms.
Figure 2 illustrates that all tests contribute separately to
information regarding pulmonary status in pre-HCTchildren.
This argues that all these screening modalities, reﬂecting
different domains of respiratory status (function, structure,
and microbial colonization), should be done in all pediatric
pre-HCT patients, if a sensitive pre-HCT screening for pul-
monary pathology is desired. The impact of the ﬁnding and
the invasiveness of the test should guide clinicians in
decision-making on whether or not to perform all tests.
As far as we know, this is the ﬁrst report on such
comprehensive pulmonary screening with PFT, HRCT, and
BAL in a large cohort of children before HCT. We have shown
considerable decrease in pulmonary function, a signiﬁcant
amount of clinical important HRCT ﬁndings, and high prev-
alence of infectious agents. This is most likely because of
underlying disease, pretreatment with chemotherapy, and
the age distribution of our patients.
In this cohort of patients, there is a signiﬁcant association
between clinically signiﬁcant HRCT ﬁndings before HCT and
lung injury after HCT. The ﬁndings in BAL and PFT were not
related with outcome. This might be due to small numbers.We might also conclude that with current treatment strate-
gies for this group of pulmonary compromised patients, we
manage to have comparable outcome.
We conclude that this screening protocol is feasible and
provides important information for risk classiﬁcation with
therapeutic consequences. We would advocate all 3
screening methods, as they all contribute separately. Pro-
spective studies are needed to further identify the impor-
tance of baseline abnormalities in the risk for pulmonary
complications and treatment-related mortality and whether
outcome is improved by using intensive screening.ACKNOWLEDGMENTS
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